BROADCASTS.com

CardioNerds cofounders Dr. Amit Goyal and Dr. Daniel Ambinder join Dr. Isabel Balachandran, Dr. Diego Celli from the Texas Heart Institute. They discuss the nuances of risk stratification management of intermediate risk pulmonary embolism. The ECPR for this episode was provided by Dr. Alam Mahboob (Associate Professor of Medicine at Baylor College of Medicine and the Department of Medicine and Associate Program Director for the Cardiovascular Disease Fellowship Program at Baylor). Audio editing by\xa0CardioNerds Academy Intern,\xa0Dr. Chelsea Amo Tweneboah.\n\n\n\n\n\n\n\nUS Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here.\n\n\n\n\n\n\n\n\n\nCardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll\n\n\n\n\n\nCardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron!\n\n\n\n\n\nCase Media - Caring for the Middle Child of Pulmonary Embolism \u2013 Texas Heart Institute\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPearls - Caring for the Middle Child of Pulmonary Embolism \u2013 Texas Heart Institute\n\n\n\n\nSubmassive pulmonary embolism is defined as an intermediate risk group of acute pulmonary embolism, which presents with signs of RV dysfunction and myocardial injury without hemodynamic instability.\n\n\n\nThe AHA, ACCP, and ESC have variable definitions of submassive PE. Non-invasive tools such as EKG, TTE, and CT are critical to defining RV dysfunction. The Pulmonary Embolism Severity Index (PESI) score is a validated tool to help risk stratify patients with PE.\n\n\n\nAdvanced therapies for submassive PE include systemic thrombolysis, catheter-based intervention, surgical embolectomy, and mechanical circulatory support. The decision between these therapies is based on individual patient risk profiles, local expertise, and the risk of major bleeding.\n\n\n\nThere is a spectrum of long-term complications after an acute PE, ranging from post PE syndrome to CTEPH (chronic thromboembolic pulmonary hypertension) caused by a maladaptive vascular remodeling from residual thrombus or arteriopathy. Thrombolytic therapies are still controversial in reducing the risk of post PE complications.\n\n\n\nPERT is a multidisciplinary group of clinicians who can rapidly assess and triage patients with acute PE, coordinate access to medical and advanced therapies, and provide the necessary follow up care.\n\n\n\n\nShow Notes - Caring for the Middle Child of Pulmonary Embolism \u2013 Texas Heart Institute\n\n\n\nHow do you define \u201csubmassive\u201d pulmonary embolism?\n\n\n\n\nVenous thromboembolism, which includes deep vein thrombosis and acute pulmonary emboli (PE) are the third most common cardiovascular disorder in the United States with approximately 900,000 cases occurring each year (1). The morbidity and mortality associated with pulmonary emboli are also great, with approximately 33% of PE cases being fatal (1).Until recently, PE was previously classified into massive or non-massive. Massive PE was defined as those with cardiogenic shock. A newer group, \u201csubmassive PE\u201d, was defined as an \u201cintermediate\u201d risk group. According to the American Heart Association (AHA) Scientific Statement on the management of massive and submassive PE, patients in this group presented with signs of RV dysfunction and myocardial necrosis without hemodynamic instability (2).\n\nIntermediate-risk PE covers a broad range of risk and management decisions remain challenging. Intermediate-risk PE convers increased risk for mortality and complications compared with low-risk PE.\xa0\n\n\n\n\n\n\nHow do you risk-stratify intermediate-risk pulmonary emboli?\n\n\n\n\nThe AHA, American College of Chest Physicians (ACCP), and European Society of Cardiology (ESC) have variable definitions of submassive PE and which biomarkers should be used (1,3). The contents are summarized as below (Table 1)\n\n\n\n\n\n\n\n\n\nEach major guideline highlights the importance of the evaluation of RV dysfunction (RVD) and elevated biomarkers. To summarize,